Hospira Recalls Propofol Injectable Emulsion, USP

Lake Forest, Ill.-based Hospira has voluntarily recalled seven lots of its Propofol Injectable Emulsion, USP, citing metal particulate embedded in the interior neck of the vial as well as free-floating metal particulates found in the vials.

Advertisement

Hospira has not received any reports of adverse events associated with these lots. However, if injected, the particulate matter could lead to local inflammation or obstructed capillaries.

More Articles on Recalls:

What the Increase in Device Recalls Means for Hospitals
Covidien Recalls Pipeline Embolization Device, Alligator Retrieval Device
Dräger Recalls Ventilator Power Supply Unit for Evita, Babylog Ventilators

Advertisement

Next Up in Supply Chain

  • Becker’s asked supply chain leaders: What’s the most productive partnership supply chain has with another department at your system, and…

  • Medline is laying off 304 workers, according to a notice filed with the state of Illinois and a Nov. 5…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.